Healthcare Industry News: Bristol-Myers Squibb
News Release - May 28, 2008
ARIAD Appoints Former Bristol-Myers Squibb Executive to Lead Corporate Legal and Compliance FunctionsCAMBRIDGE, Mass.--(HSMN NewsFeed)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA ) today announced the appointment of Raymond T. Keane, Esq., to the newly created position of vice president, general counsel and chief compliance officer. Mr. Keane, who most recently was senior counsel, worldwide medicines at Bristol-Myers Squibb (BMS), will lead the Company’s corporate legal function and be responsible for expanding and overseeing ARIAD’s commercial compliance programs. He will also assume responsibility for the Company’s legal activities relating to the commercialization of its growing pipeline of oncology product candidates.
“I am very pleased to welcome Ray to this new position on our leadership team as an experienced legal and pharmaceutical executive,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “His addition reaffirms our commitment to building a world-class organization to execute on our strategy of becoming a fully integrated oncology company.”
Mr. Keane brings almost twenty-five years of legal experience to ARIAD, the past twenty of which he spent in roles of increasing responsibility at BMS. Most recently, he served as chief counsel for all global brands, with a focus on the market development of emerging pipeline compounds, especially in the field of oncology. During his tenure at BMS, he was lead counsel to various therapeutic divisions and had primary legal responsibility for the commercialization and launch of seven BMS products.
Laurie A. Allen, Esq., senior vice president and chief legal officer of ARIAD, added, “We will benefit greatly from Ray’s counsel and the depth of his knowledge of the pharmaceutical industry. I look forward to working closely with him as we expand our business and commercial activities.”
Mr. Keane received his J.D. degree from Fordham University School of Law and his B.A. in Economics from Fordham University, College of Arts and Sciences.
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB treatment methods, and the discovery and development of drugs to regulate NF-κB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.
This press release contains “forward-looking statements.” Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the conduct and results of pre-clinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market products resulting from our development efforts, our reliance on our strategic partners and licensees and other key parties for the successful development, manufacturing and commercialization of products, the adequacy of our capital resources and the availability of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceedings concerning our NF-κB patent portfolio, the potential acquisition of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned subsidiary, ARIAD Gene Therapeutics, Inc., future capital needs, risks related to key employees, markets, economic conditions, prices, reimbursement rates and competition, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
Source: ARIAD Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.